<DOC>
	<DOCNO>NCT02341807</DOCNO>
	<brief_summary>This clinical study evaluate safety tolerability AAV2-hCHM subject Choroideremia gene mutation . Two dose group evaluate .</brief_summary>
	<brief_title>Safety Dose Escalation Study AAV2-hCHM Subjects With CHM ( Choroideremia ) Gene Mutations</brief_title>
	<detailed_description>The primary objective evaluate safety tolerability subretinal administration AAV2-hCHM , inter-subject group dose escalation individual choroideremia , base comprehensive clinical monitoring plan . The secondary objective define dose AAV2-hCHM require achieve stable , improved , visual function/functional vision ass development immune response AAV2 REP-1 .</detailed_description>
	<mesh_term>Choroideremia</mesh_term>
	<criteria>Male least 18 year age diagnose CHM gene mutation Central visual field ( VF ) &lt; 30° 24 meridian ( use Goldmann perimetry III4e isopter ) eye inject Any evidence functioning out retinal cell within central 10° Previous history ocular inflammatory disease ( uveitis ) Prior intraocular surgery within six month Participation previous gene therapy research trial within one year enrollment participation ocular gene therapy trial Participation clinical study investigational drug past six month Grossly asymmetrical disease , eye morbidity , may render contralateral eye ineffective control Visual acuity &lt; 20/200 standard ETDRS test eye inject Presence disease may preclude subject participation trial Use medication know neuroprotective retinotoxic could potentially interfere disease process and/or cause ocular adverse event ; individual discontinue use compound 6 month may become eligible Identification investigator unable unwilling perform / compliant study procedure .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Choroideremia</keyword>
	<keyword>AAV</keyword>
	<keyword>Gene therapy</keyword>
	<keyword>CHM</keyword>
	<keyword>Adeno-associated virus</keyword>
	<keyword>Adeno-associated viral vector</keyword>
</DOC>